-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$102.1073.94% Upside
Mirati Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Mirati Therapeutics, Inc.?
Mirati Therapeutics, Inc. has been rated by research analysts at Morgan Stanley, Leerink Partners, Piper Sandler, Citigroup, Oppenheimer, J.P. Morgan in the past 90 days.